Application of Dan-Chi-Liu-Wei combination in systemic lupus erythematosus patients to taper steroid use and to prevent disease flare

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN73842582

Enrollment

160

Registered

2007-02-09

Start date

2007-02-01

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus Musculoskeletal Diseases Lupus

Interventions

Use of Dan-Chi-Liu-Wei (DCLW) Chinese herbal combination (full strength) versus control (receive a 10% placebo).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Using the 1997 revised criteria for the classification of SLE over four categories: patients with mild to moderate activity (Systemic Lupus Erythematosus Disease Activity Index [SLEDAI] grade two to 12) will be recruited 2. Prednisolone use below 20 mg/day

Exclusion criteria

Exclusion criteria: 1. Currently pregnant, or plan to be pregnant (subjects who become pregnant during study at any time will be excluded) 2. Less than or equal to 18 years of age 3. More than or equal to 60 years of age 4. Serum creatinine more than or equal to 1.4 mg/dl

Design outcomes

Primary

Measure	Time frame
Dosage of steriods after six months of combined therapy (DCLW and regular drugs)	—

Secondary

Measure	Time frame
1. Frequency of disease flares after six months of combined therapy (DCLW and regular drugs) 2. Immunologic index (C3, C4, anti-ds-DeoxyriboNucleic Acid [DNA]) after six months of combined therapy (DCLW and regular drugs)	—

Countries

Taiwan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026